Clinical Trials Logo

Hyperlipoproteinemia(a) clinical trials

View clinical trials related to Hyperlipoproteinemia(a).

Filter by:
  • None
  • Page 1

NCT ID: NCT05305664 Active, not recruiting - Clinical trials for Hyperlipoproteinemia(a)

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Start date: August 19, 2022
Phase: Phase 3
Study type: Interventional

Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.

NCT ID: NCT01064934 Withdrawn - Clinical trials for Hyperlipoproteinemia(a)

Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)

ELAILa
Start date: September 2010
Phase: N/A
Study type: Interventional

Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. Non-medical treatment measures (e.g. dietary therapy or weight loss) can hardly influence Lp(a) plasma concentrations. Drug therapy has only limited influence, e.g. treatment with niacin. Statins are usually without effect. Lipid apheresis is the only treatment known to lower elevated Lp(a) levels in a relevant way. In patients with pronounced elevation of Lp(a) and normal LDL cholesterol levels, who suffer from progressive cardiovascular disease, the treatment with lipid apheresis seems to be a last-resort treatment option. The current trial will evaluate the effectiveness of lipid apheresis on cardioavascular endpoints.